EC divestment conditions on GSK/Novartis, Abbott/Mylan deals
This article was originally published in Scrip
Executive Summary
The European Commission has approved deals for both GlaxoSmithKline and Novartis, and Abbott and Mylan, but in both cases it has imposed conditions which involve divesting products.